clinical trial · NCT07415031
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.·phase2·not yet recruiting·n = 170
Solid TumorsAdagrasibPembrolizumabCetuximabPemetrexedDocetaxelIrinotecanLeucovorinOxaliplatin
brief summary
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
started
May 16, 2026
primary completion
Feb 16, 2028
completion
Feb 16, 2028
last updated
Apr 8, 2026
official title
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol